• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sera Prognostics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/5/25 5:28:00 PM ET
    $SERA
    Medical Specialities
    Health Care
    Get the next $SERA alert in real time by email
    8-K
    0001534969false00015349692025-06-052025-06-05

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): June 05, 2025

     

     

    Sera Prognostics, Inc.

    (Exact name of Registrant as Specified in Its Charter)

     

     

    Delaware

    001-40606

    26-1911522

    (State or Other Jurisdiction
    of Incorporation)

    (Commission File Number)

    (IRS Employer
    Identification No.)

     

     

     

     

     

    2749 East Parleys Way

    Suite 200

     

    Salt Lake City, Utah

     

    84109

    (Address of Principal Executive Offices)

     

    (Zip Code)

     

    Registrant’s Telephone Number, Including Area Code: (801) 990-0520

     

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:


    Title of each class

     

    Trading
    Symbol(s)

     


    Name of each exchange on which registered

    Class A Common Stock, $0.0001 par value per share

     

    SERA

     

    The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     


    Item 5.07 Submission of Matters to a Vote of Security Holders.

    On June 5, 2025, Sera Prognostics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) via live audio webcast on the Internet. Of the 36,701,381 shares of Class A common stock, par value $0.0001 per share, issued and outstanding and eligible to vote as of the record date of April 9, 2025, a quorum of 24,314,265 shares, or 66.2% of the eligible shares, was present at the meeting or represented by proxy.

    At the Annual Meeting, the stockholders: (1) elected each of Jane F. Barlow, M.D. and Mansoor Raza Mirza, M.D. to the Company’s Board of Directors as a Class I director for a term of three years to serve until the 2028 annual meeting of stockholders and until his or her successor is duly elected and qualified or until his or her earlier death, resignation, or removal (“Election of Directors”); and (2) ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 (“Auditor Ratification”). A more complete description of each of these matters is set forth in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission on April 23, 2025.

    The number of votes cast in favor or against or withheld by the stockholders and, where applicable, the number of abstentions and the number of broker non-votes on each of the foregoing matters are set forth below.

    1. Election of Directors

    Nominee

     

    Shares Voted For

     

     

    Shares Voted to Withhold Authority

     

     

    Broker Non-votes

     

    Jane F. Barlow, M.D.

     

     

    14,420,152

     

     

     

    4,895,002

     

     

     

    4,999,111

     

    Mansoor Raza Mirza, M.D.

     

     

    14,351,738

     

     

     

    4,963,416

     

     

     

    4,999,111

     

    2. Auditor Ratification

    Shares Voted For

     

    Shares Voted Against

     

    Shares Abstaining

     

    Broker Non-votes

    24,311,571

     

    2,691

     

    3

     

    —

     


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

     

    SERA PROGNOSTICS, INC.

     

     

     

     

    Date:

    June 5, 2025

    By:

    /s/ Austin Aerts

     

     

     

    Austin Aerts
    Chief Financial Officer

     


    Get the next $SERA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SERA

    DatePrice TargetRatingAnalyst
    3/30/2022$18.00 → $4.00Buy → Neutral
    Citigroup
    11/19/2021$19.00Outperform
    Oppenheimer
    10/15/2021Outperform
    Cowen
    8/9/2021Outperform
    William Blair
    8/9/2021Outperform
    Cowen
    8/9/2021$18.00Buy
    Citigroup
    More analyst ratings